Evidence map›Paper›PMID 25506198›Full record

ArticleCancer informatics2014

Trial prospector: matching patients with cancer research studies using an automated and scalable approach.

Satya S Sahoo, Shiqiang Tao, Andrew Parchman, Zhihui Luo, Licong Cui, Patrick Mergler, Robert Lanese, Jill S Barnholtz-Sloan, Neal J Meropol, Guo-Qiang Zhang

Abstract read
In one paragraph

Article in Cancer informatics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The My Cancer Genome clinical trial data model and trial curation workflow.Journal of the American Medical Informatics Association : JAMIA · 2020
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Optimizing Enrollment of Patients into Nephrology Research Studies.Clinical journal of the American Society of Nephrology : CJASN · 2016
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Satya S SahooDivision of Medical Informatics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Shiqiang TaoDivision of Medical Informatics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Andrew ParchmanDivision of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. ; University Hospitals Case Medical Center, Seidman Cancer Center, Cleveland, OH, USA.
Zhihui LuoDivision of Medical Informatics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Licong CuiDivision of Medical Informatics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Patrick MerglerUniversity Hospitals Case Medical Center, Seidman Cancer Center, Cleveland, OH, USA. ; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Robert LaneseCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Jill S Barnholtz-SloanCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA. ; Institute for Computational Biology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Neal J MeropolDivision of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. ; University Hospitals Case Medical Center, Seidman Cancer Center, Cleveland, OH, USA. ; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Guo-Qiang ZhangDivision of Medical Informatics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. ; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
NCATS NIH HHS UL1 TR000439NCI NIH HHS P30 CA043703
6 · The paper itself

Abstract

Cancer is responsible for approximately 7.6 million deaths per year worldwide. A 2012 survey in the United Kingdom found dramatic improvement in survival rates for childhood cancer because of increased participation in clinical trials. Unfortunately, overall patient participation in cancer clinical studies is low. A key logistical barrier to patient and physician participation is the time required for identification of appropriate clinical trials for individual patients. We introduce the Trial Prospector tool that supports end-to-end management of cancer clinical trial recruitment workflow with (a) structured entry of trial eligibility criteria, (b) automated extraction of patient data from multiple sources, (c) a scalable matching algorithm, and (d) interactive user interface (UI) for physicians with both matching results and a detailed explanation of causes for ineligibility of available trials. We report the results from deployment of Trial Prospector at the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center (Case CCC) with 1,367 clinical trial eligibility evaluations performed with 100% accuracy.

Indexed as

clinical decision support systemclinical oncologyclinical trialgastrointestinal cancerpatient recruitment

Identifiers

PMID25506198
PMCPMC4259509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.